Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
Both providers offer asynchronous visits (text/email) unless explicitly stated that you would like a video visit with the provider and/or your states requirements dictate that a video visit is required
Appetite suppression is the intended pharmacologic effect, but it can intensify nausea if caloric intake drops too rapidly, creating an overlap between the therapeutic effect and the adverse symptom
Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide
If you experience any of these symptoms, seek medical help immediately